Open Access Open Access  Restricted Access Subscription or Fee Access

A Review on Artificial Intelligence

Chetan Sharma

Abstract


Artificial Intelligence aims to create intelligent modelling that aids in imagining knowledge, solving problems, and making decisions. In recent years, AI has become increasingly important in areas of pharmacy such as drug discovery, drug delivery formulation development, polypharmacology, healthcare professional, and so on. In drug discovery and formulation development, Artificial Neural Networks (ANNs) including such Deep Neural Networks (DNNs) and RNN (RNNs) are used. Artificial intelligence can still save energy / cost in the pharmacy while also providing a deeper knowledge of the relationship between different formulations. Many applications of drug discovery have already be evaluated that confirmed its capability of the technique in structure - property connection (QSPR) and quantitative structure-activity relationship (QSAR). Furthermore, de novo creation encourages the development of much newer pharmacological compounds with desired/optimal properties.


Full Text:

PDF

References


Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773-80.

Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019; 151:169-90.

Russel S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. AI Mag. 2015;36(4):105-14.

Duch W, Setiono R, Zurada JM. Computational intelligence methods for rulebased data understanding. Proc IEEE. 2004;92(5):771-805.

Dasta JF. Application of artificial intelligence to pharmacy and medicine. Hosp Pharm. 1992;27(4):319-22.

Jiang F, Jiang Y, Zhi H. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc Neurol. 2017;2(4):230-43.

Gobburu JV, Chen EP. Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. J Pharm Sci. 1996;85(5):505-10.

Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol. 2009;5(2):149-69.

Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. J Pharm Biomed Anal. 2000;22(5):717-27.

Zhang ZH, Wang Y, Wu WF, Zhao X, Sun XC, Wang HQ. Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network. Yao Xue Xue Bao. 2012;47(12):1687-95.

Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure–activity relationships. J Chem Inf Model. 2015;55(2):263-74.

Mayr A, Klambauer G, Unterthiner T, Hochreither S. Deep Tox: Toxicity prediction using Deep Learning. Front Environ Sci. 2016; 3:80.

Bishop CM. Model-based machine learning. Philos Trans A Math Phys Eng Sci. 2013;371(1984):20120222.

Merk D, Friedrich L, Grisoni F, Schneider G. De novo design of bioactive small molecules by artificial intelligence. Mol Inform. 2018;37(1-2):1-4.

Manikiran SS, Prasanthi NL. Artificial Intelligence: Milestones and Role in Pharma and Healthcare Sector. Pharma Times. 2019;51(1):10-1.

Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic resistant superbugs. ACS Chem Biol. 2009;4(1):65- 74.

Haykin S. Neural Networks: A Comprehensive Foundation, 1st ed. PrenticeHall PTR. NJ, United State. 1998.

Zupan J, Gasteiger J. Neural nets for mass and vibrational spectra. J Mol Struct. 1993 ;292:141-59.

Achanta AS, Kowalski JG, Rhodes CT. Artificial neural networks: Implications for pharmaceutical sciences. Drug Dev Ind Pharm. 1995;21(1):119-55.

Sakiyama Y. The use of machine learning and nonlinear statistical tools for ADME prediction. Expert Opin Drug Metab Toxicol. 2009;5(2):149-69.

Sutariya V, Groshev A, Sadana P, Bhatia D, Pathak Y. Artificial neural network in drug delivery and pharmaceutical research. Open Bioinf J. 2013;7(1):49-62.

Gutiérrez PA, Hervás-Martínez C. Hybrid Artificial Neural Networks: Models, Algorithms and Data. Advances in Computational Intelligence, Lecture Notes in Computer Science, Springer, Berlin, Heidelberg. 2011;6692.

Taskinen J, Yliruusi J. Prediction of physicochemical properties based on neural network modeling. Adv Drug Deliv Rev. 2003;55(9):1163-83.

Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018;557(7706):S55-7.

Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery systems. Adv Drug Deliv Rev. 2003;55(9):1201-15.

Zadeh LA. Fuzzy sets. Inform Control. 1965;8:338-53.

Huang JW, Roy RJ. Multiple-drug hemodynamic control using fuzzy decision theory. IEEE Transact Biomed Eng. 1998;45(2):213-28.

Held CM, Roy RJ. Multiple drug hemodynamic control by means of a supervisory fuzzy rule-based adaptive control system: Validation on a model. IEEE Trans Biomed Eng. 1995;42(4):371-85.

Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Mullertz A. In vitro– in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm. 2008;699(3):887- 98.

Jolliffe IT, Jorge C. Principal component analysis: A review and recent developments. Phil Trans R Soc A. 2016;374(2065):20150202.

Jolliffe IT Principal Component Analysis” Springer-Verlag, (New York). 2002.

Giuliani A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov Today. 2017;22(7):1069-76.

Burges CJC. A tutorial on support vector machines for pattern recognition. Data Mining Knowledge Discov. 1998;2(2):121-67.

Heba FE, Darwish A, Hassanien AE, Abraham A. Principle components analysis and support vector machine based intrusion detection system, 10th International Conference on Intelligent Systems Design and Applications, Cairo. 2010;363-7.

Heikamp K, Bajorath J. Support vector machines for drug discovery. Expert Opin Drug Discov. 2014;9(1):93-104.

Maltarollo VG, Kronenberger T, Espinoza GZ, Oliveira PR, Honorio KM. Advances with support vector machines for novel drug discovery. Expert Opin Drug Discov. 2019;14(1):23-33.

Burbidge R, Trotter M, Buxton B, Holden S. Drug design by machine learning: Support vector machines for pharmaceutical data analysis. Comput Chem. 2001;26(1):5-14.

Ljung L. Black-box models from input-output measurements. In Proceedings of the 18th IEEE Instrumentation and Measurement Technology Conference. Rediscovering Measurement in the Age of Informatics (Cat. No.01CH 37188), Budapest, Hungary. 2001;138–146.21.

Patcharaprakiti N, Kirtikara K, Chenvidhya D, Monyakul V, Muenpinij B. Modeling of single phaseinverter of photovoltaic system using system identification. In Proceedings of the 2010 Second International Conference on Computer and Network Technology, Bangkok, Thailand. 2010;462-6.

Shokrollahi E, Goldenberg AA, Drake JM, Eastwood KW, Kang M. Application of a nonlinear Hammerstein-Wiener estimator in the development and control of a magnetorheological fluid haptic device for robotic bone biopsy. Actuators. 2018;7(4):83.

Silver D, Schrittwieser J, Simonyan K. Mastering the game of Go without human knowledge. Nature. 2017;550(7676):354-9.

Lakdawala AS, Okafo G, Baldoni J, Palovich M, Sikosek T, Sahni V. Adapting drug discovery to artificial intelligence. Drug Target Rev. 2018;50-2.

Reymond JL, Deursen RV, Blum LC, Ruddigkeit L. Chemical space as a source for new drugs. Med Chem Commun. 2010;1(1):30-8.

Ferrero E, Dunham I, Sanseau P. In silico prediction of novel therapeutic targets using gene-disease association data. J Transl Med. 2017;15(1):182.

Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT. Computational approaches in target identification and drug discovery. Comput Struct Biotechnol J. 2016; 14:177- 84.

Yuan Y, Pei J, Lai L. Lig Builder 2: A practical de novo drug design approach. J Chem Inf Model. 2011;51(5):1083-91.

Merk D, Friedrich L, Grisoni F, Schneider G. De novo Design of Bioactive Small Molecules by Artificial Intelligence Daniel. Mol Inform. 2018;37(1-2):201700153.

Blaschke T, Olivecrona M, Engkvist O, Bajorath J, Chen H. Application of Generative Autoencoder in de nov Molecular Design. Mol Inform. 2018;37(1- 2):201700123.

Gupta A, Müller AT, Huisman BJH, Fuchs JA, Schneider P, Schneider G. Generative Recurrent Networks for de nov Drug Design. Mol Inform. 2018;37(1- 2):201700111.

Ferrero E, Dunham I, Sanseau P. In silico prediction of novel therapeutic targets using gene-disease association data. J Transl Med. 2017;15(1):182.


Refbacks

  • There are currently no refbacks.